NATIONAL MEDICAL CARE COMPANY Financials National Medical Care Company
Equities
4005
SA139051UIH0
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 184.2 SAR | +2.22% |
|
-3.66% | +5.62% |
| Apr. 22 | Saudi Arabia's National Medical Care Co Declares FY23 Dividend | MT |
| Apr. 22 | National Medical Care Wins SAR380 Million Contract for Patient Care Services | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,180 | 2,395 | 2,808 | 3,314 | 7,822 | 8,082 | - | - |
| Enterprise Value (EV) 1 | 1,901 | 2,117 | 2,522 | 3,068 | 7,783 | 7,500 | 7,301 | 7,236 |
| P/E ratio | 27.2 x | 24.6 x | 20.6 x | 19.5 x | 32.5 x | 28.2 x | 23.5 x | 22.6 x |
| Yield | 4.12% | 3.75% | 1.6% | 1.35% | - | 0.96% | 1.06% | 1.26% |
| Capitalization / Revenue | 3.08 x | 2.96 x | 3.32 x | 3.61 x | 7.23 x | 5.88 x | 5.42 x | 4.91 x |
| EV / Revenue | 2.68 x | 2.62 x | 2.98 x | 3.34 x | 7.19 x | 5.46 x | 4.89 x | 4.4 x |
| EV / EBITDA | 11 x | 12.4 x | 12.3 x | 12.5 x | 26.8 x | 19.6 x | 16.7 x | 15.2 x |
| EV / FCF | 12.5 x | 22.7 x | 43.4 x | 538 x | 18.9 x | 208 x | 36 x | 28.4 x |
| FCF Yield | 8% | 4.4% | 2.3% | 0.19% | 5.3% | 0.48% | 2.78% | 3.52% |
| Price to Book | 2.11 x | 2.31 x | 2.5 x | 2.62 x | 5.38 x | 4.89 x | 4.26 x | 3.79 x |
| Nbr of stocks (in thousands) | 44,850 | 44,850 | 44,850 | 44,850 | 44,850 | 44,850 | - | - |
| Reference price 2 | 48.60 | 53.40 | 62.60 | 73.90 | 174.4 | 180.2 | 180.2 | 180.2 |
| Announcement Date | 2/23/20 | 3/29/21 | 3/1/22 | 3/5/23 | 2/27/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 708.4 | 809 | 845.4 | 917.9 | 1,082 | 1,374 | 1,492 | 1,645 |
| EBITDA 1 | 172.9 | 170.3 | 205.4 | 244.5 | 290.3 | 383.1 | 437.8 | 477 |
| EBIT 1 | 104.8 | 114.1 | 155.3 | 198.8 | 246.7 | 318.7 | 358.7 | 398.3 |
| Operating Margin | 14.8% | 14.11% | 18.37% | 21.66% | 22.81% | 23.19% | 24.05% | 24.21% |
| Earnings before Tax (EBT) 1 | 102.7 | 123.3 | 164.4 | 198.5 | 264.6 | 333.2 | 392.7 | 392.3 |
| Net income 1 | 80.09 | 97.27 | 136.4 | 170.1 | 240.9 | 293.4 | 350.4 | 382.2 |
| Net margin | 11.31% | 12.02% | 16.13% | 18.53% | 22.27% | 21.36% | 23.49% | 23.23% |
| EPS 2 | 1.790 | 2.170 | 3.040 | 3.790 | 5.370 | 6.399 | 7.666 | 7.989 |
| Free Cash Flow 1 | 152 | 93.18 | 58.11 | 5.703 | 412.7 | 36.1 | 202.6 | 254.4 |
| FCF margin | 21.46% | 11.52% | 6.87% | 0.62% | 38.15% | 2.63% | 13.59% | 15.47% |
| FCF Conversion (EBITDA) | 87.93% | 54.71% | 28.29% | 2.33% | 142.17% | 9.42% | 46.28% | 53.34% |
| FCF Conversion (Net income) | 189.84% | 95.8% | 42.62% | 3.35% | 171.31% | 12.3% | 57.83% | 66.58% |
| Dividend per Share 2 | 2.000 | 2.000 | 1.000 | 1.000 | - | 1.736 | 1.908 | 2.273 |
| Announcement Date | 2/23/20 | 3/29/21 | 3/1/22 | 3/5/23 | 2/27/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 213.1 | 215.6 | 211.5 | 216.5 | 238.3 | 251.7 | 261.4 | 245.2 | 275.4 | 299.8 | 322.3 |
| EBITDA | - | - | 46.04 | - | 60.45 | 58.18 | - | - | - | - | - |
| EBIT 1 | 39.8 | 35.71 | 37.01 | 45.95 | 49.06 | 46.95 | 63.43 | - | 74.89 | - | 77 |
| Operating Margin | 18.67% | 16.57% | 17.5% | 21.23% | 20.59% | 18.66% | 24.27% | - | 27.2% | - | 23.89% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 33.17 | 36.71 | 30 | 42.01 | 42.62 | 55.45 | 56.27 | 47.8 | 73.38 | 63.48 | 68.33 |
| Net margin | 15.57% | 17.03% | 14.19% | 19.4% | 17.89% | 22.03% | 21.53% | 19.49% | 26.65% | 21.17% | 21.2% |
| EPS 2 | 0.7400 | - | - | - | 0.9500 | 1.230 | 1.250 | 1.070 | 1.640 | 1.410 | 1.560 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/1/22 | 5/16/22 | 8/11/22 | 11/2/22 | 3/5/23 | 5/14/23 | 8/7/23 | 11/5/23 | 2/27/24 | - |
1SAR in Million2SAR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 279 | 278 | 286 | 246 | 38.9 | 582 | 781 | 846 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 152 | 93.2 | 58.1 | 5.7 | 413 | 36.1 | 203 | 254 |
| ROE (net income / shareholders' equity) | 7.89% | 9.4% | 12.6% | 14.2% | 17.7% | 18.6% | 18.1% | 19% |
| ROA (Net income/ Total Assets) | 5.82% | 6.98% | 9.11% | 10.4% | 12.3% | 14.1% | 14.1% | 14% |
| Assets 1 | 1,376 | 1,394 | 1,496 | 1,636 | 1,964 | 2,081 | 2,485 | 2,730 |
| Book Value Per Share 2 | 23.00 | 23.10 | 25.10 | 28.20 | 32.40 | 36.80 | 42.30 | 47.60 |
| Cash Flow per Share 2 | 3.600 | 2.380 | 2.090 | 4.840 | 10.40 | 5.970 | 7.660 | 8.420 |
| Capex 1 | 9.79 | 13.5 | 35.7 | 211 | 54 | 145 | 157 | 125 |
| Capex / Sales | 1.38% | 1.67% | 4.22% | 23.01% | 4.99% | 10.57% | 10.52% | 7.58% |
| Announcement Date | 2/23/20 | 3/29/21 | 3/1/22 | 3/5/23 | 2/27/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
180.2
SAR
Average target price
204.4
SAR
Spread / Average Target
+13.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.33% | 2.16B | |
| -17.07% | 16.85B | |
| +3.60% | 12.34B | |
| +5.64% | 11.77B | |
| +4.26% | 10.28B | |
| +25.36% | 8.38B | |
| -0.68% | 7.88B | |
| +22.18% | 7.29B | |
| +5.77% | 6.75B | |
| +52.00% | 4.69B |
- Stock Market
- Equities
- 4005 Stock
- Financials National Medical Care Company
